The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

In this article, we focus on the reimbursement process, and as an example, characterize the time to reimbursement of pembrolizumab, a PD-1 immune checkpoint inhibitor for treatment of metastatic NSCLC from publicly available websites, in three different healthcare systems: The National Institute for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharman Moser, Sarah, Tanser, Frank, Siegelmann-Danieli, Nava, Apter, Lior, Chodick, Gabriel, Solomon, Josie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936745/
https://www.ncbi.nlm.nih.gov/pubmed/36797806
http://dx.doi.org/10.1186/s40545-023-00529-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936745/
https://www.ncbi.nlm.nih.gov/pubmed/36797806
http://dx.doi.org/10.1186/s40545-023-00529-0

Ejemplares similares